Francisco J. Esteva - Publications, H-index & Citations

Francisco J. Esteva

northwell health

80H指数

457论文数

2.8W被引数

收录论文 146

发表时间

Multi-modal AI for comprehensive breast cancer prognostication 多模态AI用于全面乳腺癌预后评估

Nature Communications

IF15.7

2026-05-20

OAAI

Jan Witowski; Ken G. Zeng; Joseph Cappadona; Jailan Elayoubi; Khalil Choucair; Elena Diana Chiru; Nancy Chan; Young-Joon Kang; Frederick Howard; Irina Ostrovnaya; Carlos Fernandez-Granda; Freya Schnabel; Zoe Steinsnyder; Ugur Ozerdem; Kangning Liu; Waleed Abdulsattar; Yu Zong; Lina Daoud; Rafic Beydoun; Anas M. Saad; Nitya Thakore; Mohammad Sadic; Frank Yeung; Elisa Liu; Theodore Hill; Benjamin Swett; Danielle Rigau; Andrew J. Clayburn; Valerie Speirs; Marcus Vetter; Lina Sojak; Simone Muenst; Daniel Baumhoer; Jia-Wern Pan; Haslina Makmur; Soo-Hwang Teo; Linda M. Pak; Victor Angel; Dovile Zilenaite-Petrulaitiene; Arvydas Laurinavicius; Natalie Klar; Brian D. Piening; Carlo Bifulco; Sun-Young Jun; Jae Pak Yi; Su Hyun Lim; Adam Brufsky; Francisco J. Esteva; Lajos Pusztai; Yann LeCun; Krzysztof J. Geras

Expert Perspectives on Controversies and Critical Knowledge Gaps in Breast Cancer Management: Proceedings of the First Bridging the Gaps in Breast Cancer Symposium 乳腺癌管理中的争议与关键知识空白专家观点：第一届弥合乳腺癌知识空白研讨会的会议录

Clinical Breast Cancer

IF2.5

2025-04-08

PREAI

Komal Jhaveri; Carey K. Anders; Aditya Bardia; Manali Bhave; A. Jo Chien; Ian Krop; Tiffany A. Traina; Yara Abdou; Reva Basho; Alison K. Conlin; Francisco J. Esteva; Kevin R. Fox; Vijayakrishna Gadi; Peter A. Kaufman; Anya Litvak; Cynthia X. Ma; Eleftherios P. Mamounas; Heather McArthur; Kelly McCann; Zahi Mitri; Rebecca Shatsky; Melinda Telli; Mylin A. Torres; Kevin Kalinsky

Long-term overall survival of patients who undergo breast-conserving therapy or mastectomy for early operable HER2-Positive breast cancer after preoperative systemic therapy: an observational cohort study

LANCET REGIONAL HEALTH-AMERICAS

IF7.6

2024-04-01

OAAI

He, Xuexin; Ji, Jiali; Qdaisat, Aiham; Esteva, Francisco J.; Yeung, Sai-Ching J.

Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2,-3 and-7 trials in hormone receptor-positive, HER2-negative advanced breast cancer

BRITISH JOURNAL OF CANCER

IF6.8

2021-06-22

OAAI

Burris, Howard A.; Chan, Arlene; Bardia, Aditya; Thaddeus Beck, J.; Sohn, Joohyuk; Neven, Patrick; Tripathy, Debu; Im, Seock-Ah; Chia, Stephen; Esteva, Francisco J.; Hart, Lowell; Zarate, Juan Pablo; Ridolfi, Antonia; Lorenc, Karen Rodriguez; Yardley, Denise A.

Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors

CLINICAL CANCER RESEARCH

IF10.2

2021-06-11

OAAI

He, Xuexin; Ji, Jiali; Dai, Xiaolan; Qdaisat, Aiham Z.; Esteva, Francisco J.; Hortobagyi, Gabriel N.; Yeung, Sai-Ching J.

Whole-genome screen identifies diverse pathways that negatively regulate ciliogenesis

MOLECULAR BIOLOGY OF THE CELL

IF2.7

2021-01-15

OAAI

Failler, Marion; Giro-Perafita, Ariadna; Owa, Mikito; Srivastava, Shalini; Yun, Chi; Kahler, David J.; Unutmaz, Derya; Esteva, Francisco J.; Sanchez, Irma; Dynlacht, Brian D.

Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

BREAST

IF7.9

2020-12-01

OAAI

Fasching, Peter A.; Beck, J. Thaddeus; Chan, Arlene; De Laurentiis, Michele; Esteva, Francisco J.; Jerusalem, Guy; Neven, Patrick; Pivot, Xavier; Bianchi, Giulia V.; Martin, Miguel; Chandiwana, David; Lanoue, Brad; Ridol, Antonia; Wang, Yingbo; Lorenc, Karen Rodriguez; Nusch, Arnd

Gene expression profiling in immunophenotypic triple negative breast carcinomas harboring HER-2 amplification identifies tumors with distinct molecular signatures and increased ERBB2 gene expression

CANCER RESEARCH

IF16.6

2020-02-15

PREAI

Cotzia, Paolo; Vougiouklakis, Theodore; Andreo, Ursula; Jour, George; Schwartz, Christopher; Kwa, Maryann; Adams, Sylvia; Esteva, Francisco; Axelrod, Deborah; Schnabel, Freya; Snuderl, Matija; Darvishian, Farbod

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2020-02-06

504

OAAI

Slamon, Dennis J.; Neven, Patrick; Chia, Stephen; Fasching, Peter A.; De Laurentiis, Michelino; Im, Seock-Ah; Petrakova, Katarina; Bianchi, Giulia V.; Esteva, Francisco J.; Martin, Miguel; Nusch, Arnd; Sonke, Gabe S.; De la Cruz-Merino, Luis; Beck, J. Thaddeus; Pivot, Xavier; Sondhi, Manu; Wang, Yingbo; Chakravartty, Arunava; Rodriguez-Lorenc, Karen; Taran, Tetiana; Jerusalem, Guy

LncRNA RP11-19E11 is an E2F1 target required for proliferation and survival of basal breast cancer

NPJ BREAST CANCER

IF7.6

2020-01-06

OAAI

Giro-Perafita, A.; Luo, L.; Khodadadi-Jamayran, A.; Thompson, M.; Oksuz, B. Akgol; Tsirigos, A.; Dynlacht, B. D.; Sanchez, I.; Esteva, F. J.

Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer

CLINICAL CANCER RESEARCH

IF10.2

2019-12-13

OAAI

He, Xuexin; Ji, Jiali; Tian, Mei; Esteva, Francisco J.; Hortobagyi, Gabriel N.; Yeung, Sai-Ching Jim

DRUGS

IF14.4

2019-09-20

PREAI

Zinzani, Pier Luigi; Dreyling, Martin; Gradishar, William; Andre, Marc; Esteva, Francisco J.; Boulos, Suliman; Barca, Eva Gonzalez; Curigliano, Giuseppe

Clinical development of CT-P6 in HER2 positive breast cancer

EXPERT OPINION ON BIOLOGICAL THERAPY

IF4

2019-09-11

PREAI

Fu, Chen; Stebbing, Justin; Esteva, Francisco J.

Breast cancer risk in relation to plasma metabolites among Hispanic and African American women (vol 176, pg 687, 2019)

BREAST CANCER RESEARCH AND TREATMENT

IF3

2019-06-01

OAAI

Zhao, Hua; Shen, Jie; Moore, Steven C.; Ye, Yuanqing; Wu, Xifeng; Esteva, Francisco J.; Tripathy, Debasish; Chow, Wong-Ho

A plasma protein derived TGFβ signature is a prognostic indicator in triple negative breast cancer

NPJ PRECISION ONCOLOGY

IF8

2019-04-02

OAAI

Katayama, Hiroyuki; Tsou, Peiling; Kobayashi, Makoto; Capello, Michela; Wang, Hong; Esteva, Francisco; Disis, Mary L.; Hanash, Samir

24 months results from a double-blind, randomized phase III trial comparing the efficacy and safety of neoadjuvant then adjuvant trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC)

CANCER RESEARCH

IF16.6

2019-02-15

PREAI

Esteva, F. J.; Lee, S.; Yu, S.; Kim, M.; Kim, N.; Stebbing, J.

Ribociclib plus endocrine therapy in patients with hormone receptor-positive, HER2-negative advanced breast cancer presenting with visceral metastases: Subgroup analysis of phase III MONALEESA trials

CANCER RESEARCH

IF16.6

2019-02-15

PREAI

Yardley, D. A.; Chan, A.; Nusch, A.; Sonke, G. S.; Yap, Y-S; Bachelot, T.; Esteva, F. J.; Slamon, D. J.; Burris, H. A.; Gaur, A.; Kong, O.; Diaz-Padilla, I.; Lorenc, K. Rodriguez; Wheatley-Price, P.

First-line ribociclib plus endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled efficacy analysis

CANCER RESEARCH

IF16.6

2019-02-15

PREAI

Tripathy, D.; Hortobagyi, G.; Chan, A.; Im, S-A; Chia, S.; Yardley, D.; Esteva, F. J.; Hurvitz, S.; Kong, O.; Bao, W.; Lorenc, K. Rodriguez; Diaz-Padilla, I.; Slamon, D. J.

Breast cancer risk in relation to plasma metabolites among Hispanic and African American women

BREAST CANCER RESEARCH AND TREATMENT

IF3

2019-02-15

OAAI

Zhao, Hua; Shen, Jie; Moore, Steven C.; Ye, Yuanqing; Wu, Xifeng; Esteva, Francisco J.; Tripathy, Debasish; Chow, Wong-Ho

Results from KATE2, a randomized phase 2 study of atezolizumab (atezo) plus trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+advanced breast cancer (BC)

CANCER RESEARCH

IF16.6

2019-02-15

PREAI

Emens, L. A.; Esteva, F.; Beresford, M.; Saura, C.; De laurentiis, M.; Kim, S-B; Im, S-A; Patre, M.; Wang, Y.; Mani, A.; Liu, H.; de Haas, S.; Loi, S.

研究方向